NAD+ Clinical Review 2026 | NNM & NR

A brand new NAD clinical review in the journal Aging Cell highlights some critical issues with NAD and NAD boosters such as NMN and NR. However more importantly, it also uncovers exactly what we can do to optimize NAD and its precursors. This really is unmissable information that you simply won't find on other channels. Exclusive DoNotAge 10% Discount Code: RYKER https://donotage.org/products This code will work for all donotage products including subscriptions and special offers. Enjoy! NMN Presentation: https://youtu.be/Em75xD7Ps6s?si=zwg7U4xxtyMGojpD STUDY LINKS: The Aging Cell review is pivotal because it shifts the focus from "healthy aging" (where results are mixed) to "pathological aging" and DNA repair disorders, where NAD+ boosters show the most clinical significance. Below is the list of the primary clinical and landmark studies analyzed in the review, categorized by their focus area. 1. The Main Review: NAD+ in Premature Aging Study: Promising Results With NAD Supplementation in Rare Diseases With Premature Aging and DNA Damage Authors: Bohr VA, 2025 Journal: Aging Cell Primary Link: https://onlinelibrary.wiley.com/doi/10.1111/acel.70319 Free Access (PMC): https://pmc.ncbi.nlm.nih.gov/articles/PMC12727671/ 2. The Werner Syndrome NR Trial Authors: Shoji M et al., 2025 Journal: Aging Cell Primary Link (PubMed): https://pubmed.ncbi.nlm.nih.gov/40459998/ Free Access (PMC): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12341770/ Relevance: Supports the claims in paragraph 8 regarding the 140% NAD+ increase, improved CAVI scores, and skin ulcer healing in Werner Syndrome patients. 3. The Ataxia-Telangiectasia (A-T) NR Trial (Short-Term) Authors: Veenhuis SJG et al., 2021 Journal: Movement Disorders Primary Link (PubMed): https://pubmed.ncbi.nlm.nih.gov/34515380/ Free Access (PMC): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291897/ Relevance: Supports the claim in paragraph 10 about NR improving ataxia scores in A-T patients. 4. The Ataxia-Telangiectasia (A-T) NR Trial (Long-Term) Authors: Presterud R et al., 2024 Journal: Movement Disorders Primary Link (PubMed): https://pubmed.ncbi.nlm.nih.gov/37899683/ Free Access (Journal): https://movementdisorders.onlinelibrary.wiley.com/doi/10.1002/mds.29645 Relevance: Supports the claim in paragraph 10 about the 2-year NR trial improving motor coordination. 5. The NMN Transporter (SLC12A8) Authors: Grozio A et al., 2019 Journal: Nature Metabolism Primary Link: https://www.nature.com/articles/s42255-018-0009-4 Free Access (PMC): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6530925/ Relevance: Supports the claim in paragraph 11 that NMN has its own dedicated transporter. 6. The Mitochondrial NAD+ Transporter (SLC25A51) Authors: Luongo TS et al., 2020 Journal: Nature Primary Link: https://www.nature.com/articles/s41586-020-2741-7 Free Access (PMC): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7718333/ Relevance: Supports the claims in paragraphs 16-17 about the "gatekeeper" protein for mitochondrial NAD+. 7. CD38 and NAD+ Decline Authors: Camacho-Pereira J et al., 2016 Journal: Cell Metabolism Primary Link (Free Access): [https://www.cell.com/cell-metabolism/fulltext/S1550-4131(16 )30224-8](https://www.cell.com/cell-metabolism/fulltext/S1550-4131(16 )30224-8) Free Access (PMC): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4911708/ Relevance: Supports the claim in paragraph 4 that CD38 is a major consumer of NAD+ that increases with age and inflammation. 8. Apigenin as a CD38 Inhibitor Authors: Escande C et al., 2013 Journal: Diabetes Primary Link (PubMed): https://pubmed.ncbi.nlm.nih.gov/23172919/ Free Access (PMC): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3609577/ Relevance: Supports the claim in paragraph 21 that apigenin can inhibit CD38. 9. Human Tissue-Specific NAD+ Decline Study: Age-Associated Changes In Oxidative Stress and NAD+ Metabolism In Human Tissue Authors: Massudi H et al., 2012 Journal: PLOS ONE Primary Link (Free Access): https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0042357 Free Access (PMC): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3407129/ Relevance: Supports the claim in paragraph 3 that NAD+ decline is tissue-specific in humans, with skin being one of the first affected. 10. TMG for Methylation Support Study: Nicotinamide Riboside—The Current State of Research and Therapeutic Uses Authors: Mehmel M et al., 2020 Journal: Nutrients Primary Link (Free Access): https://www.mdpi.com/2072-6643/12/6/1616 Free Access (PMC): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352172/ Relevance: This review explains the metabolic pathway where excess nicotinamide is methylated for excretion, supporting the rationale in paragraph 22 for using TMG as a methyl donor. Get my complete daily longevity supplement protocol and latest anti-aging research sent straight to your inbox. Join my mailing list at https://rykerblack.com